Table 4.
Associations of pre-finasteride-treatment 5α-androstane-3α,17β-diol glucuronide, sex steroid hormones and sex hormone binding globulin with prostate cancer risk.
| Overall Cancer | Gleason 2–6 | Gleason 7–10 | Gleason 8–10 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Range of values | N case/ctl | OR (95% CI)2 | N case/ctl | OR (95% CI)2 | N case/ctl | OR (95% CI)2 | N case/ctl | OR (95% CI)2 | |
| 3α-dG1 | <(3.9) | 156/169 | ref | 96/169 | ref | 58/169 | ref | 21/169 | ref |
| (ng/mL) | (3.9) to <(5.7) | 144/166 | 0.93 (0.67–1.28) | 84/166 | 0.87 (0.60–1.27) | 56/166 | 0.98 (0.63–1.52) | 19/166 | 0.91 (0.47–1.78) |
| (5.7) to <(8.0) | 142/167 | 0.87 (0.63–1.20) | 73/167 | 0.72 (0.49–1.06) | 57/167 | 0.96 (0.62–1.48) | 19/167 | 0.90 (0.46–1.75) | |
| ≥(8.0) | 130/172 | 0.80 (0.58–1.11) | 74/172 | 0.73 (0.50–1.07) | 52/172 | 0.88 (0.57–1.37) | 17/172 | 0.82 (0.41–1.63) | |
| Pslope | 0.17 | 0.07 | 0.58 | 0.58 | |||||
| Testosterone | <(289) | 167/170 | ref | 90/170 | ref | 71/170 | ref | 27/170 | ref |
| (ng/dL) | (289) to <(363) | 128/165 | 0.78 (0.56–1.09) | 71/165 | 0.78 (0.52–1.15) | 53/165 | 0.79 (0.51–1.22) | 13/165 | 0.50 (0.25–1.02) |
| (363) to <(457) | 159/166 | 0.92 (0.66–1.29) | 95/166 | 0.97 (0.66–1.42) | 58/166 | 0.84 (0.54–1.30) | 21/166 | 0.77 (0.40–1.47) | |
| ≥ (457) | 118/173 | 0.64 (0.43–0.93) | 71/173 | 0.63 (0.40–1.00) | 41/173 | 0.57 (0.34–0.97) | 15/173 | 0.50 (0.23–1.12) | |
| Pslope | 0.07 | 0.15 | 0.07 | 0.18 | |||||
| Free Testosterone | <(6.8) | 147/170 | ref | 82/170 | ref | 61/170 | ref | 23/170 | ref |
| (ng/dL) | (6.8) to <(8.5) | 167/166 | 1.16 (0.84–1.60) | 92/166 | 1.12 (0.77–1.63) | 69/166 | 1.19 (0.79–1.81) | 21/166 | 1.00 (0.53–1.90) |
| (8.5) to <(10.2) | 139/166 | 0.99 (0.72–1.38) | 86/166 | 1.05 (0.71–1.54) | 48/166 | 0.88 (0.56–1.38) | 18/166 | 0.95 (0.49–1.86) | |
| ≥ (10.2) | 119/172 | 0.83 (0.59–1.17) | 67/172 | 0.77 (0.52–1.16) | 45/172 | 0.83 (0.53–1.32) | 14/172 | 0.78 (0.37–1.61) | |
| Pslope | 0.21 | 0.22 | 0.25 | 0.49 | |||||
| Estrone | <(35.8) | 137/166 | ref | 72/166 | ref | 60/166 | ref | 17/166 | ref |
| (pg/mL) | (35.8) to <(44.0) | 128/172 | 0.93 (0.67–1.29) | 67/172 | 0.93 (0.62–1.39) | 55/172 | 0.91 (0.59–1.39) | 19/172 | 1.06 (0.53–2.13) |
| (44.0) to <(54.5) | 138/163 | 1.12 (0.81–1.57) | 85/163 | 1.32 (0.89–1.95) | 51/163 | 0.94 (0.61–1.46) | 21/163 | 1.33 (0.67–2.63) | |
| ≥ (54.5) | 161/167 | 1.38 (0.99–1.93) | 99/167 | 1.68 (1.14–2.48) | 54/167 | 1.00 (0.64–1.55) | 19/167 | 1.12 (0.55–2.28) | |
| Pslope | 0.03 | 0.00 | 0.98 | 0.62 | |||||
| Total Estradiol | <(26.7) | 138/164 | ref | 69/164 | ref | 66/164 | ref | 19/164 | ref |
| (pg/mL) | (26.7) to <(33.3) | 142/168 | 1.02 (0.73–1.41) | 85/168 | 1.24 (0.83–1.84) | 49/168 | 0.72 (0.46–1.11) | 21/168 | 1.01 (0.52–1.98) |
| (33.3) to <(40.4) | 146/166 | 1.13 (0.81–1.57) | 92/166 | 1.44 (0.97–2.14) | 46/166 | 0.73 (0.46–1.14) | 16/166 | 0.81 (0.40–1.66) | |
| ≥ (40.4) | 145/172 | 1.11 (0.79–1.55) | 81/172 | 1.25 (0.83–1.88) | 61/172 | 0.95 (0.62–1.46) | 20/172 | 0.96 (0.48–1.91) | |
| Pslope | 0.45 | 0.22 | 0.82 | 0.76 | |||||
| Free Estradiol | <(0.73) | 136/169 | ref | 68/169 | ref | 63/169 | ref | 19/169 | ref |
| (pg/mL) | (0.73) to <(0.90) | 123/165 | 0.92 (0.66–1.29) | 71/165 | 1.09 (0.73–1.63) | 49/165 | 0.78 (0.50–1.20) | 15/165 | 0.77 (0.38–1.58) |
| (.90) to <(1.10) | 137/166 | 1.17 (0.83–1.63) | 92/166 | 1.65 (1.11–2.45) | 40/166 | 0.69 (0.43–1.09) | 21/166 | 1.15 (0.59–2.25) | |
| ≥ (1.10) | 132/170 | 1.12 (0.80–1.57) | 71/170 | 1.27 (0.84–1.91) | 55/170 | 0.94 (0.61–1.46) | 13/170 | 0.71 (0.33–1.51) | |
| Pslope | 0.31 | 0.09 | 0.65 | 0.64 | |||||
1
5α-androstane-3α,17β-diol glucuronide
2
Adjusted for age, race, family history of prostate cancer, SHBG, body mass index and serum cholesterol.